Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy. SONAR: Study Of Diabetic Nephropathy With Atrasentan

NCT01858532 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01858532
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01858532 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy. SONAR: Study Of Diabetic Nephropathy With Atrasentan
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Terminated
Start date
May 17, 2013
Completion date
March 29, 2018
Enrollment
5,107 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic nephropathy